Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.08Last Year’s EPS
-0.33Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2025
|% Change Since: 33.05%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
GeneDx reported strong financial performance with significant revenue and margin growth driven by the success of their exome and genome testing. They are making strategic investments to fuel future growth, including expanding their sales force and launching new products. However, challenges remain with high denial rates on test reimbursements and the decision to exit the hereditary cancer segment.Company Guidance
During the GeneDx Fourth Quarter 2024 Earnings Conference Call, the company provided guidance for 2025, projecting revenues in the range of $350 million to $360 million, with at least 30% growth in both exome and genome volume and revenue. The fourth quarter of 2024 saw revenues surpass $95 million, with adjusted gross margins expanding to 70%. GeneDx has positioned itself as a leader in exome and genome testing, and plans to invest further in growth, scale, innovation, and talent to accelerate market development. The company is focusing on leveraging its unique technology to achieve efficiencies in the U.S. healthcare system and aims to capitalize on opportunities in the NICU and outpatient settings. GeneDx also plans to exit the hereditary cancer business in 2025 to concentrate on its core areas. The company is committed to maintaining profitability each quarter throughout 2025.Record Revenue and Growth
GeneDx's fourth quarter 2024 revenues from continuing operations reached $95.3 million. Exome and genome revenues grew 101% year-over-year and 31% sequentially, contributing $78.8 million this quarter.
Gross Margin Expansion
Adjusted gross profit from continuing operations in the fourth quarter was $66.9 million, translating to an adjusted gross margin of 70%, up from 56% a year ago and 64% last quarter.
Exome and Genome Testing Success
Exome and genome tests accounted for 38% of all tests in the fourth quarter, up from 27% a year ago. Over 20,000 of these tests were delivered, up 32% year-over-year.
Strong Cash Position
Cash, cash equivalents, marketable securities, and restricted cash totaled $142.2 million as of December 31, 2024.
Guidance for 2025
GeneDx expects total revenues between $350 million to $360 million for full year 2025 with at least 30% growth in exome and genome volume and revenue.
---
WGS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
WGS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 18, 2025 | $76.35 | $112.76 | +47.69% |
| Oct 29, 2024 | $56.06 | $84.02 | +49.88% |
| Jul 30, 2024 | $30.13 | $32.72 | +8.60% |
| Apr 29, 2024 | $11.00 | $17.07 | +55.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GeneDx Holdings (WGS) report earnings?
GeneDx Holdings (WGS) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is GeneDx Holdings (WGS) earnings time?
GeneDx Holdings (WGS) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is WGS EPS forecast?
WGS EPS forecast for the fiscal quarter 2025 (Q1) is 0.08.
---